{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:19:54Z","timestamp":1789651194320,"version":"4.0.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.bmc.2022.116812","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T21:03:51Z","timestamp":1652907831000},"page":"116812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Structure-activity relationships of 2-pyrimidinecarbohydrazides as utrophin modulators for the potential treatment of Duchenne muscular dystrophy"],"prefix":"10.1016","volume":"69","author":[{"given":"Maria","family":"Chatzopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Conole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Emer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Rowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicky J.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Squire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Brough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis X.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham M.","family":"Wynne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay E.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela J.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2022.116812_b0005","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/jhg.2014.54","article-title":"New variants, challenges and pitfalls in DMD genotyping: implications in diagnosis, prognosis and therapy","volume":"59","author":"Santos","year":"2014","journal-title":"J Hum Genet"},{"key":"10.1016\/j.bmc.2022.116812_b0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.coph.2017.04.002","article-title":"Pharmacological advances for treatment in Duchenne muscular dystrophy","volume":"34","author":"Guiraud","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.bmc.2022.116812_b0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/21678707.2018.1438261","article-title":"The potential of utrophin modulators for the treatment of Duchenne muscular dystrophy","volume":"6","author":"Guiraud","year":"2018","journal-title":"Expert Opin Orphan Drugs"},{"key":"10.1016\/j.bmc.2022.116812_b0020","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/323646a0","article-title":"Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene","volume":"323","author":"Monaco","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2022.116812_b0025","doi-asserted-by":"crossref","unstructured":"Birnkrant DJ, Bushby K, Bann, CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 2018;17:251\u201367. https:\/\/doi.org\/10.1016\/S1474-4422(18)30024-3.","DOI":"10.1016\/S1474-4422(18)30024-3"},{"key":"10.1016\/j.bmc.2022.116812_b0030","doi-asserted-by":"crossref","unstructured":"Nakamura A. Mutation-based therapeutic strategies for Duchenne muscular dystrophy: from genetic diagnosis to therapy. J Pers Med 2019;9. https:\/\/doi.org\/10.3390\/jpm9010016.","DOI":"10.3390\/jpm9010016"},{"key":"10.1016\/j.bmc.2022.116812_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107719","article-title":"Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy","volume":"220","author":"Iftikhar","year":"2021","journal-title":"Pharmacol Therapeut"},{"key":"10.1016\/j.bmc.2022.116812_b0040","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/nm1197-1216","article-title":"Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice","volume":"3","author":"Deconinck","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.bmc.2022.116812_b0045","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/4033","article-title":"Expression of full-length utrophin prevents muscular dystrophy in mdx mice","volume":"4","author":"Tinsley","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.bmc.2022.116812_b0050","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/jcph.468","article-title":"Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to healthy male adult volunteers","volume":"55","author":"Tinsley","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2022.116812_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152840","article-title":"Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to pediatric patients with duchenne muscular dystrophy","volume":"11","author":"Ricotti","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmc.2022.116812_b0060","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/cpdd.642","article-title":"A phase 1b trial to assess the pharmacokinetics of ezutromid in pediatric duchenne muscular dystrophy patients on a balanced diet","volume":"8","author":"Muntoni","year":"2019","journal-title":"Clin Pharm Drug Dev"},{"key":"10.1016\/j.bmc.2022.116812_b0065","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1021\/acs.jmedchem.9b01547","article-title":"Isolation, structural identification, synthesis, and pharmacological profiling of 1,2-trans-dihydro-1,2-diol metabolites of the utrophin modulator ezutromid","volume":"63","author":"Chatzopoulou","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116812_b0070","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.0c00807","article-title":"2-Arylbenzo[d]oxazole phosphinate esters as second-generation modulators of utrophin for the treatment of Duchenne Muscular Dystrophy","author":"Babbs","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116812_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.tet.2019.130819","article-title":"Synthesis of SMT022357 enantiomers and in vivo evaluation in a Duchenne muscular dystrophy mouse model","volume":"76","author":"Babbs","year":"2020","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bmc.2022.116812_b0080","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1093\/hmg\/ddv154","article-title":"Second-generation compound for the modulation of utrophin in the therapy of DMD","volume":"24","author":"Guiraud","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.bmc.2022.116812_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113431","article-title":"Discovery and mechanism of action studies of 4,6-diphenylpyrimidine-2-carbohydrazides as utrophin modulators for the treatment of Duchenne muscular dystrophy","volume":"220","author":"Vuorinen","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2022.116812_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116614","article-title":"Structural modification aimed for improving solubility of lead compounds in early phase drug discovery","volume":"56","author":"Das","year":"2022","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2022.116812_b0095","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1021\/jm901241e","article-title":"Escape from flatland: increasing saturation as an approach to improving clinical success","volume":"52","author":"Lovering","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116812_b0100","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","article-title":"The role of ligand efficiency metrics in drug discovery","volume":"13","author":"Hopkins","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2022.116812_b0105","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1021\/ci500588j","article-title":"DataWarrior: an open-source program for chemistry aware data visualization and analysis","volume":"55","author":"Sander","year":"2015","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2022.116812_b0110","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1081\/SCC-120021834","article-title":"Efficient synthesis of a complete donor\/acceptor bis(Aryl)diyne family","volume":"33","author":"Holmes","year":"2003","journal-title":"Synth Commun"},{"key":"10.1016\/j.bmc.2022.116812_b0115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF01086149","article-title":"Pharmacokinetics of Isoniazid Metabolism in Man","volume":"4","author":"Ellard","year":"1976","journal-title":"J Pharmacokinetics Biopharmaceutics"},{"key":"10.1016\/j.bmc.2022.116812_b0120","first-page":"1072","article-title":"Rifampin-Induced Release of Hydrazine from Isoniazid","volume":"133","author":"Raghupati Sarma","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.bmc.2022.116812_b9000","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1021\/jm200135z","article-title":"Discovery of 2-Arylbenzoxazoles as Upregulators of Utrophin Production for the Treatment of Duchenne Muscular Dystrophy","volume":"54","author":"Chancellor","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116812_b9005","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/anie.201912392","article-title":"Chemical Proteomics and Phenotypic Profiling Identifies the Aryl Hydrocarbon Receptor as a Molecular Target of the Utrophin Modulator Ezutromid","volume":"59","author":"Wilkinson","year":"2020","journal-title":"Angew Chem Int Ed"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622002048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622002048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:20:07Z","timestamp":1760836807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089622002048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":26,"alternative-id":["S0968089622002048"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2022.116812","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-activity relationships of 2-pyrimidinecarbohydrazides as utrophin modulators for the potential treatment of Duchenne muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2022.116812","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116812"}}